Skip to main content

Table 2 Measures of therapeutic efficacy of AL before and after PCR correction

From: Efficacy and safety of artemether-lumefantrine for the treatment of uncomplicated malaria and prevalence of Pfk13 and Pfmdr1 polymorphisms after a decade of using artemisinin-based combination therapy in mainland Tanzania

Outcome Kibaha
n (%; 95% CI)
Mlimba
n (%; 95% CI)
Mkuzi
n (%; 95% CI)
Ujiji
n (%; 95% CI)
Total
n (%; 95% CI)
PCR uncorrected
 Parasitaemia on day 3 0 (0; 0–4.5) 2 (2.3; 0.3–8.1) 5 (5.7; 1.9–12.9) 4 (4.7; 1.3–11.5) 11 (3.3;1.7–5.8)
 ETF 0 (0; 0–4.7) 0 (0; 0–4.2) 0 (0; 0–4.2) 1 (1.1%; 0–6.2) 1 (0.3; 0–1.7)
 LCF 12 (15.8; 8.4–26.0) 2 (2.3; 0.3–8.1) 3 (3.5; 0.7–9.9) 4 (4.6; 1.3–11.4) 21 (6.3; 3.9–9.4)
 LPF 6 (7.9; 3.0–16.4) 11 (12.8; 6.6–21.7) 11 (12.8; 6.6–21.7) 19 (21.8; 13.7–32.0) 47 (14.0; 10.5–18.2)
 ACPR 58 (76.3; 65.2–85.3) 73 (84.9; 75.5–91.7) 72 (83.7; 74.2–90.8) 63 (72.4; 61.8–81.5) 266 (79.4; 74.7–83.9)
 Total for per protocol 76 86 86 87 335
 Withdrawn 0 (0.0%) 1 (1.1) 1 (1.1) 1 (1.1) 3 (0.9%)
 Lost to follow-up 4 (5.0%) 1 (1.1) 1 (1.1) 0 (0) 6 (1.7%)
 Total at baseline 80 88 88 88 344
PCR corrected
 ETF 0 (0; 0–6.2) 0 (0; 0–4.9) 0 (0; 0–4.9) 1 (1.6;) 1 (0.4; 0–2.1)
 LCF 0 (0; 0–6.2) 0 (0; 0–4.9) 1 (1.4:) 0 (0; 0–5.6) 1 (0.4; 0–2.1)
 LPF 0 (0; 0–6.2) 0 (0; 0–4.9) 0 (0; 0–4.9) 0 (0; 0–5.6) 0 (0; 0–1.4)
 ACPR 58 (100; 93.8–100) 73 (100; 95.1–100) 72 (98.6; 92.6–100) 63 (98.4; 91.6–100) 266 (99.3; 97.3–99.9)
 Total for per protocol 58 73 73 64 268
 Withdrawn/lost to follow-up 4 (5.0%) 2 (2.2) 2 (2.2) 1 (1.1) 9 (2.6)
 Re-infection 15 (18.8) 11 (12.5) 9 (10.2) 20 (22.7) 55 (16.0)
 Unknown PCRa 3 (3.4) 2 (0.6) 4 (1.2) 3 (3.4) 12 (3.5)
 Total at baseline 80 88 88 88 344
 KM cumulative success rate 58 (100) 73 (100) 72 (98.6) 63 (98.4) 266 (99.3)
  1. ACPR: adequate clinical and parasitological response; ETF: early treatment failure; LCF: late clinical failure; LPF: late parasitological failure; PP: number of patients involve in the per protocol analysis; KM: Kaplan–Meier
  2. aThe samples could not be resolved after PCR because of inconsistent PCR results